FDA staff calls for more studies on Depakote's risks

06/22/2009 | Reuters

Additional studies must be done to prove that Abbott Laboratories' anti-seizure drug Depakote does not cause developmental delay in children, FDA staff members recommended. Employees issued a memo in light of six reports of delayed development, including two cases of autism, in children exposed to Depakote since its approval in 1983. Abbott said it will continue working with the agency "to further evaluate any risks related to anti-epileptic drugs, neurodevelopment and pregnancy."

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ